ArticleNanotechnology, science and applications2026
Functionalized Colloidal Hydroxyapatite for Combined Delivery of Cannabidiol and Epirubicin: Characterization, Biomimetic Membrane Interaction, and Cytotoxicity Studies.
Article in Nanotechnology, science and applications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A stable colloidal hydroxyapatite (cHAp) platform was successfully developed for the co-delivery of cannabidiol (CBD), a natural bioactive compound, and epirubicin (EPI), a chemotherapeutic agent, to enhance cytotoxicity against ovarian cancer cells. Methods: Colloidal cHAp was synthesized and functionalized with CBD and EPI to obtain a multifunctional drug delivery system. The resulting composite was characterized using high-performance liquid chromatography, UV-Vis spectrometry, transmission and scanning electron microscopies, Fourier-transform infrared spectroscopy, Turbiscan analysis, and differential scanning calorimetry. Drug release in phosphate-buffered saline (PBS, pH 7) was evaluated by differential pulse voltammetry. Interactions with model lipid monolayers mimicking healthy and cancerous cell membranes were investigated using the Langmuir technique, and cytotoxicity was assessed by MTS assays. Results: The successful incorporation of both biologically active compounds into the cHAp carrier and its excellent colloidal stability were confirmed. The epirubicin loading content was 0.0605 mg per 1 mg of cHAp. Drug release followed a time-dependent profile, reaching approximately 2 μg mL Conclusion: The developed cHAp platform provides a stable and multifunctional carrier for the co-delivery of CBD and epirubicin. Its favorable physicochemical properties, enhanced membrane interactions, and improved anticancer activity highlight its potential as a promising nanocarrier for targeted ovarian cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.